Although a potential goldmine for the future of medicine, nanotechnology is still not fully understood by many. Richard Moore of the Institute of Nanotechnology shares his thoughts with Lorrie Kelly on the future of nanomaterials within medicine and how regulations must evolve as innovation continues.
Richard Moore of Eucomed argues for the risk-based approach to regulation used in the medical device field. He believes it provides the best framework for the regulation of human tissue-engineered products in the EU.
The application of new and convergent technologies on the nanoscale is already making devices more patient-friendly. Richard Moore, Eucomed, looks at the opportunities and challenges ahead for a promising area of development.